Spero Therapeutics, Inc. (SPRO) financial statements (2021 and earlier)

Company profile

Business Address 675 MASSACHUSETTS AVENUE
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments8211587
Cash and cash equivalents303487
Short-term investments5281 
Deferred costs 0 
Other undisclosed current assets1385
Total current assets:9512492
Noncurrent Assets
Operating lease, right-of-use asset5
Property, plant and equipment231
Deposits noncurrent assets 00
Restricted cash and investments  0
Other noncurrent assets41 
Other undisclosed noncurrent assets01 
Total noncurrent assets:1151
TOTAL ASSETS:10612993
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities876
Accounts payable443
Accrued liabilities111
Employee-related liabilities321
Debt1  
Deferred rent credit 0
Derivative instruments and hedges, liabilities 00
Deferred revenue and credits0
Other undisclosed current liabilities1852
Total current liabilities:27128
Noncurrent Liabilities
Long-term debt and lease obligation5  
Long-term debt, excluding current maturities0  
Operating lease, liability5
Liabilities, other than long-term debt 10
Deferred revenue and credits0
Deferred rent credit 1
Total noncurrent liabilities:510
Total liabilities:32139
Stockholders' equity
Stockholders' equity attributable to parent7511685
Common stock000
Additional paid in capital274254181
Accumulated other comprehensive income (loss)0(0) 
Accumulated deficit(199)(139)(97)
Stockholders' equity attributable to noncontrolling interest 00
Total stockholders' equity:7511685
TOTAL LIABILITIES AND EQUITY:10612993

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
Revenue, net2
Gross profit:1842
Operating expenses(81)(47)(44)
Operating loss:(63)(43)(42)
Nonoperating income212
Investment income, nonoperating1  
Foreign currency transaction loss, before tax (0)(0)
Other nonoperating income112
Other undisclosed income from continuing operations before equity method investments, income taxes 00
Net loss:(61)(42)(40)
Net income attributable to noncontrolling interest  1
Other undisclosed net income attributable to parent0  
Net loss attributable to parent:(61)(42)(39)
Preferred stock dividends and other adjustments  (6)
Other undisclosed net loss available to common stockholders, basic  (1)
Net loss available to common stockholders, diluted:(61)(42)(46)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
Net loss:(61)(42)(40)
Other comprehensive loss (0) 
Comprehensive loss:(61)(42)(40)
Comprehensive income, net of tax, attributable to noncontrolling interest  1
Other undisclosed comprehensive income, net of tax, attributable to parent0  
Comprehensive loss, net of tax, attributable to parent:(61)(42)(39)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: